ABO INCOMPATIBLE KIDNEY TRANSPLANTATION - ONE CENTRE EXPERIENCE
Author(s): ,
Marco Sampaio
Affiliations:
Serviço de Hematologia Clínica,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
Marika Bini Antunes
Affiliations:
Serviço de Hematologia Clínica,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
Jorge Malheiro
Affiliations:
Serviço de Nefrologia,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
Leonídio Dias
Affiliations:
Serviço de Nefrologia,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
La Salete Martins
Affiliations:
Serviço de Nefrologia,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
Sofia Pedroso
Affiliations:
Serviço de Nefrologia,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
Manuela Almeida
Affiliations:
Serviço de Nefrologia,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
António Castro Henriques
Affiliations:
Serviço de Nefrologia,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
Sandra Tafulo
Affiliations:
Centro de Histocompatibilidade do Norte,Instituto Português do Sangue e da Transplantação,Porto,Portugal
,
Rita Oliveira
Affiliations:
Serviço de Hematologia Clínica,Centro Hospitalar e Universitário do Porto,Porto,Portugal
,
Francisca Vasconcelos
Affiliations:
Serviço de Hematologia Clínica,Centro Hospitalar e Universitário do Porto,Porto,Portugal
Margarida Amil
Affiliations:
Serviço de Hematologia Clínica,Centro Hospitalar e Universitário do Porto,Porto,Portugal
EHA Library. Sampaio M. Jun 14, 2019; 266609; PF810
Dr. Marco Sampaio
Dr. Marco Sampaio
Contributions
Abstract

Abstract: PF810

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background

Donor living kidney transplantation (KT) is an available optionfor end-stage renal disease, improving survival and quality of life when compared with other treatments. ABO incompatibility was considered an important barrier for long but, with the increasing organ shortage and due to improvement of immunosuppression protocols, ABO-incompatible (ABOi) KT has achieved remarkable success in the last decades, with graft survivals and patient overall survivals comparable to compatible transplantations. Consensually, initial goal is to lower patient ABO antibodies titter to ≤1:16 before transplantation, ≤1:8 during the first week and ≤1:16 during the second week after surgery. Thereafter, even a rebound of ABO antibodies does not appear to harm the graft due to accommodation phenomenon. Current strategies for desensitization include B‑cell‑depleting therapies and intensified immunosuppression as well as plasmapheresis to remove ABO antibodies. 

Aims
Retrospective evaluation of donor/recipient pairs proposed for ABOi Kidney transplantation between 2015 and 2018.

Methods

Donor-patient pairs were proposed by the Kidney Transplantation Centre. Patients were evaluated for ABO/Rh group, relationship with donor, diagnosis, pre-KT isoagglutinin anti-A and anti-B (IgG and IgM), pre-KT donor specific HLA antibodies, post-KT isoagglutinin titter (daily up to D14, at D30, and at sixth month after KT), number of plasmapheresis performed (target: IgG isoagglutinin <1: 8 between D0-D7 and <1:16 to D14), graft function titter (serum creatinine), transfusion support, significant associated complications and overall patient survival. An initial IgG isoagglutinin titter >1: 512 was considered contraindication for KT as well as the presence of donor specific anti-HLA antibodies. Immunosuppression protocol included rituximab and basiliximab for B cell depletion and standard triple immunosuppression with tacrolimus, mofetil mycophenolate and corticosteroids.

Results

We studied 43 donor-receptor pairs for ABOi-KT over a period of four years. Sixteen patients were excluded due to ABO IgG titters >1:512 and 10 out of 17 pairs considered suitable for transplantation were transplanted in the considered period.

Results are summarized in table 1.

Graft survival so far is 100% on a follow-up period between 7 and 49 months. All patients are independent from dialysis and the creatinine level has steady levels (average of 1.61 mg/dL).  However, in one patient a renal biopsy performed at sixteenth month documented an incipient glomerulopathy, even if ABO titters maintained low and no evidence of HLA Ab was found out.

Conclusion
The presented results are in accordance with those described by some authors and confirm that ABOi KT is a viable alternative for the treatment of patients with chronic kidney disease, permit to expand the living donor pool and to reduce the time access to transplantation. 

Session topic: 31. Transfusion medicine

Keyword(s): ABO blood group, Transplant

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies